0
     

Report Added
Report already added
Hemato Oncology Testing Market by Product & Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid, Acute Lymphocytic), Lymphoma (Non-Hodgkin, Hodgkin), Technology (PCR, NGS), End User - Global Forecast to 2027

Hemato Oncology Testing Market by Product & Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid, Acute Lymphocytic), Lymphoma (Non-Hodgkin, Hodgkin), Technology (PCR, NGS), End User - Global Forecast to 2027

The global Hemato oncology testing market is projected to reach USD 5.6 billion by 2027 from an estimated USD 2.9 Billion in 2022, at a CAGR of 14.2%. The growth in this market is attributed to the growing incidence of hematologic cancer, increasing collaborations, and the increasing number of conferences on personalized medicine.

“The Services segment accounted for the highest growth rate in the Hemato oncology testing market, by product and services type, during the forecast period”

On the basis of products & services type, the global hemato oncology testing market is segmented into services and assay kits.

In 2021, The services segment accounted for the largest share of the global hemato oncology testing market in 2021. This can be attributed to the increase in the number of hematologic cancer significantly. Hence the the patient needs continuous monitoring and testing during the treatment, the increasing collaration between the companies for conducting the clinical trails on the hematologic cancers requires the hemato oncology testing products and the raising number of the diagonostic centers for diagonotic testing procudures is expected to boost the demand for the the services segment in the hemato oncology testing product market .

“Lymphoma segment accounted for the highest CAGR by cancer type, during the forecast period”

By cancer type, the global leukemia, lymphoma, and other cancers market. In 2021, the lymphoma segment dominated the global market. This can be attributed to factor such as the increasing prevalence lymphoma and the risisng geriatric population across sthe globe is supporting the increasing incidence of the lymphoma cases which is a major driving factor for this market.

“The PCR segment accounted for the highest growth rate in the Hemato oncology testing market, by technology type, during the forecast period”
Based on type, the Hemato oncology testing market technology is segmented into PCR, IHC, NGS, cytogenetics, and other technologies.

In 2021, the PCR segment dominated hemato oncology testing market. Factors supporting the growth of the segment is the wide use of this technology owing to its ease of use and easy availability of assay kits.

“The Asia-Pacific market is expected to grow at the highest CAGR during the forecast period.”

The Hemato oncology testing market is segmented into - North America, Europe, the Asia Pacific and ROW. The Hemato oncology testing market in several Asia-Pacific countries is expected to witness high growth during the forecast period. Market growth will be driven by the rising geriatric population, increasing demand for quality healthcare, and the growing focus on cancer biomarkers by various stakeholders in their respective healthcare systems.

A breakdown of the primary participants referred to for this report is provided below:
•By Company Type: Tier 1–45%, Tier 2–35%, and Tier 3– 45%
•By Designation: C-level–32%, Director-level–20%, and Others–48%
•By Region: North America–35%, Europe–28%, Asia Pacific–25%, ROW¬—12%

Lists of Companies Profiled in the Report:
•Abbott Laboratories (US)
•F. Hoffman-La Roche (Switzerland)
•QIAGEN (Germany)
•Thermo Fisher Scientific (US)
•Illumina (US)
•Bio-Rad Laboratories (US)q
•MolecularMD (Ireland)
•ArcherDX (US)
•ARUP Laboratories (US)
•Asuragen (US)
•Invivoscribe (US)
•Adaptive Biotechnologies (US)
•Amoy Diagnostics (China)
•ELITechGroup (France)
• Vela Diagnostics (Singapore)
•Gentronix (UK)
•BioIVT (US)
•SAGA Diagnostics (Sweden)
•Olink (Sweden)
•Cancer Diagnostics (US)

Research Coverage
This report studies the Hemato oncology testing market based on the type of product, cancer, technology and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Hemato oncology testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities and challenges.
Table of Contents

1INTRODUCTION20
1.1STUDY OBJECTIVES20
1.2MARKET DEFINITION20
1.2.1INCLUSIONS & EXCLUSIONS21
1.3STUDY SCOPE21
FIGURE 1MARKETS COVERED21
1.3.1REGIONAL SCOPE22
1.3.2YEARS CONSIDERED22
1.4CURRENCY CONSIDERED22
1.5LIMITATIONS23
1.6MARKET STAKEHOLDERS23
1.7SUMMARY OF CHANGES23
2RESEARCH METHODOLOGY25
2.1RESEARCH DATA25
FIGURE 2RESEARCH DESIGN25
2.2SECONDARY DATA26
2.2.1SECONDARY SOURCES26
2.2.2KEY DATA FROM SECONDARY SOURCES26
2.3PRIMARY DATA27
FIGURE 3PRIMARY SOURCES27
2.3.1KEY DATA FROM PRIMARY SOURCES28
2.3.2KEY INDUSTRY INSIGHTS29
2.4BREAKDOWN OF PRIMARY INTERVIEWS29
FIGURE 4BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS29
FIGURE 5BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION30
2.5MARKET SIZE ESTIMATION30
FIGURE 6HEMATO-ONCOLOGY TESTING MARKET: BOTTOM-UP APPROACH31
2.5.1GROWTH FORECAST32
FIGURE 7CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS32
2.5.2TOP-DOWN APPROACH33
FIGURE 8HEMATO-ONCOLOGY TESTING MARKET: TOP-DOWN APPROACH33
2.6MARKET BREAKDOWN AND DATA TRIANGULATION34
FIGURE 9DATA TRIANGULATION METHODOLOGY34
2.7RESEARCH ASSUMPTIONS35
2.8STUDY ASSUMPTIONS35
2.9INDICATORS AND OTHER ASSUMPTIONS36
2.10RISK ASSESSMENT36
TABLE 1RISK ASSESSMENT36
2.11RESEARCH LIMITATIONS36
3EXECUTIVE SUMMARY37
FIGURE 10HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)37
FIGURE 11HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2022 VS. 2027 (USD MILLION)38
FIGURE 12HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)38
FIGURE 13HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)39
FIGURE 14HEMATO-ONCOLOGY TESTING MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)39
4PREMIUM INSIGHTS41
4.1HEMATO-ONCOLOGY TESTING MARKET OVERVIEW41
FIGURE 15GROWING INCIDENCE OF HEMATOLOGIC CANCERS TO DRIVE MARKET GROWTH41
4.2NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE (2021)42
FIGURE 16HEMATO-ONCOLOGY TESTING SERVICES DOMINATED NORTH AMERICAN MARKET IN 202142
4.3GEOGRAPHICAL SNAPSHOT OF HEMATO-ONCOLOGY TESTING MARKET42
FIGURE 17NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 202142
5MARKET OVERVIEW43
5.1INTRODUCTION43
5.2MARKET DYNAMICS43
FIGURE 18HEMATO-ONCOLOGY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES43
5.2.1DRIVERS44
5.2.1.1Growing incidence of hematologic cancer44
TABLE 1GLOBAL HEMATOLOGIC CANCER INCIDENCE, BY TYPE, 2020–204044
TABLE 2GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 203044
5.2.1.2Increasing collaborations between companies45
5.2.1.3Rising number of private diagnostic centers45
5.2.1.4Increasing conferences on personalized medicine46
TABLE 3HEMATO-ONCOLOGY TESTING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS, 2022–202346
5.2.2RESTRAINTS47
5.2.2.1Unfavorable reimbursement scenario47
TABLE 4REIMBURSEMENT SCENARIO FOR HEMATO-ONCOLOGY TESTING PRODUCTS ACROSS REGIONS47
5.2.2.2Complex regulatory frameworks delaying approval of new molecular diagnostic tests48
5.2.2.3High capital investments and low cost-benefit ratio for biomarkers48
5.2.3OPPORTUNITIES48
5.2.3.1Emerging markets48
TABLE 5CAPITAL HEALTH EXPENDITURE, BY COUNTRY, 201949
TABLE 6INCIDENCE OF HEMATOLOGIC CANCERS, BY COUNTRY, 2020 VS. 204049
5.2.3.2Drug diagnostics co-development49
5.2.4CHALLENGES50
5.2.4.1Intellectual property rights protection issues50
5.2.4.2Shortage of trained professionals50
6HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE51
6.1INTRODUCTION52
TABLE 7HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)52
6.2SERVICES52
6.2.1RISING INCIDENCE OF HEMATOLOGIC CANCERS TO INCREASE DEMAND FOR HEMATO-ONCOLOGY SERVICES52
TABLE 8HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)53
TABLE 9HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)53
6.3ASSAY KITS53
6.3.1GROWING FOCUS ON DEVELOPMENT OF ADVANCED ASSAY KITS TO DRIVE GROWTH53
TABLE 10HEMATO-ONCOLOGY TESTING ASSAY KITS MARKET, BY REGION, 2020–2027 (USD MILLION)54
7HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE55
7.1INTRODUCTION56
TABLE 11HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)56
7.2LEUKEMIA56
FIGURE 19GLOBAL LEUKEMIA INCIDENCE, 202057
TABLE 12HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY REGION, 2020–2027 (USD MILLION)57
TABLE 13HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)58
7.2.1ACUTE MYELOID LEUKEMIA58
7.2.1.1High incidence of AML in adults to drive growth58
TABLE 14HEMATO-ONCOLOGY TESTING MARKET FOR ACUTE MYELOID LEUKEMIA, BY REGION, 2020–2027 (USD MILLION)58
7.2.2ACUTE LYMPHOCYTIC LEUKEMIA58
7.2.2.1High incidence of ALL in children to support growth58
TABLE 15HEMATO-ONCOLOGY TESTING MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2020–2027 (USD MILLION)59
7.2.3OTHER LEUKEMIAS59
TABLE 16HEMATO-ONCOLOGY TESTING MARKET FOR OTHER LEUKEMIAS, BY REGION, 2020–2027 (USD MILLION)59
7.3LYMPHOMA60
TABLE 17HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY REGION, 2020–2027 (USD MILLION)60
TABLE 18HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)60
7.3.1NON-HODGKIN LYMPHOMA61
7.3.1.1Non-Hodgkin lymphoma to dominate market during forecast period61
FIGURE 20GLOBAL INCIDENCE OF NON-HODGKIN LYMPHOMA, 202061
TABLE 19HEMATO-ONCOLOGY TESTING MARKET FOR NON-HODGKIN LYMPHOMA, BY REGION, 2020–2027 (USD MILLION)61
7.3.2HODGKIN LYMPHOMA62
7.3.2.1APAC hemato-oncology testing market for Hodgkin lymphoma to grow at highest rate62
FIGURE 21GLOBAL INCIDENCE OF HODGKIN LYMPHOMA, 202062
TABLE 20HEMATO-ONCOLOGY TESTING MARKET FOR HODGKIN LYMPHOMA, BY REGION, 2020–2027 (USD MILLION)62
7.4OTHER CANCERS63
TABLE 21HEMATO-ONCOLOGY TESTING MARKET FOR OTHER CANCERS, BY REGION, 2020–2027 (USD MILLION)63
8HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY64
8.1INTRODUCTION65
TABLE 22HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)65
8.2PCR65
8.2.1PCR TECHNOLOGY TO DOMINATE HEMATO-ONCOLOGY TESTING MARKET65
TABLE 23HEMATO-ONCOLOGY TESTING MARKET FOR PCR, BY REGION, 2020–2027 (USD MILLION)66
8.3IHC66
8.3.1ABILITY TO VISUALIZE TARGETED COMPONENTS IN SAMPLES TO BOOST ADOPTION66
TABLE 24HEMATO-ONCOLOGY TESTING MARKET FOR IHC, BY REGION, 2020–2027 (USD MILLION)66
8.4NGS67
8.4.1NGS SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD67
TABLE 25HEMATO-ONCOLOGY TESTING MARKET FOR NGS, BY REGION, 2020–2027 (USD MILLION)67
8.5CYTOGENETICS67
8.5.1HEAVY DEPENDENCE ON CYTOGENETIC ANALYSIS FOR DIAGNOSIS OF LEUKEMIA AND LYMPHOMA TO FUEL GROWTH67
TABLE 26HEMATO-ONCOLOGY TESTING MARKET FOR CYTOGENETICS, BY REGION, 2020–2027 (USD MILLION)68
8.6OTHER TECHNOLOGIES68
TABLE 27HEMATO-ONCOLOGY TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)69
9HEMATO-ONCOLOGY TESTING MARKET, BY END USER70
9.1INTRODUCTION71
TABLE 28HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)71
9.2CLINICAL LABORATORIES71
9.2.1PRESENCE OF ADVANCED INFRASTRUCTURE TO DRIVE MARKET71
TABLE 29HEMATO-ONCOLOGY TESTING MARKET FOR CLINICAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION)72
9.3HOSPITALS72
9.3.1HIGH PATIENT FOOTFALL TO SUPPORT GROWTH72
TABLE 30HEMATO-ONCOLOGY TESTING MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION)72
9.4ACADEMIC & RESEARCH INSTITUTES73
9.4.1GROWING MEDICAL RESEARCH AND DRUG DEVELOPMENT IN ACADEMIC & RESEARCH INSTITUTES TO FUEL GROWTH73
TABLE 31HEMATO-ONCOLOGY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)73
9.5OTHER END USERS73
TABLE 32HEMATO-ONCOLOGY TESTING MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)74
10HEMATO-ONCOLOGY TESTING MARKET, BY REGION75
10.1INTRODUCTION76
TABLE 33HEMATO-ONCOLOGY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)76
10.2NORTH AMERICA76
FIGURE 22NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET SNAPSHOT77
TABLE 34NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)77
TABLE 35NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)78
TABLE 36NORTH AMERICA: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)78
TABLE 37NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)78
TABLE 38NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)79
TABLE 39NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)79
TABLE 40NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)79
TABLE 41NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)80
10.2.1US80
10.2.1.1US to dominate North American hemato-oncology testing market during forecast period80
TABLE 42US: LEUKEMIA AT A GLANCE80
TABLE 43US: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)81
TABLE 44US: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)81
TABLE 45US: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)82
TABLE 46US: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)82
TABLE 47US: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)82
TABLE 48US: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)83
TABLE 49US: HEMATO-ONCOLOGY TESTING MARKET, BY END USER,
2020–2027 (USD MILLION)83
10.2.2CANADA83
10.2.2.1Initiatives undertaken by healthcare authorities to support growth of market83
TABLE 50CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)84
TABLE 51CANADA: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)84
TABLE 52CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)84
TABLE 53CANADA: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)85
TABLE 54CANADA: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)85
TABLE 55CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)85
TABLE 56CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)86
10.3EUROPE86
10.3.1RISING FOCUS ON BIOMARKER DEVELOPMENT IN EU COUNTRIES TO SUPPORT MARKET86
TABLE 57EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)86
TABLE 58EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)87
TABLE 59EUROPE: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)87
TABLE 60EUROPE: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)87
TABLE 61EUROPE: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)88
TABLE 62EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)88
TABLE 63EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)88
10.4ASIA PACIFIC89
10.4.1ASIA PACIFIC MARKET TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD89
FIGURE 23ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET SNAPSHOT89
TABLE 64ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)90
TABLE 65ASIA PACIFIC: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)90
TABLE 66ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)90
TABLE 67ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)91
TABLE 68ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)91
TABLE 69ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)91
TABLE 70ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)92
10.5REST OF THE WORLD92
TABLE 71REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)92
TABLE 72REST OF THE WORLD: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)93
TABLE 73REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)93
TABLE 74REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)93
TABLE 75REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)94
TABLE 76REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)94
TABLE 77REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)94
11COMPETITIVE LANDSCAPE95
11.1OVERVIEW95
11.2STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN95
TABLE 78OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HEMATO-ONCOLOGY TESTING MARKET95
11.3MARKET SHARE ANALYSIS, 202196
TABLE 79HEMATO-ONCOLOGY TESTING MARKET: DEGREE OF COMPETITION96

11.4COMPANY EVALUATION MATRIX97
11.4.1STARS97
11.4.2EMERGING LEADERS97
11.4.3PERVASIVE PLAYERS98
11.4.4PARTICIPANTS98
FIGURE 24HEMATO-ONCOLOGY TESTING MARKET: COMPETITIVE LEADERSHIP MAPPING (2021)98
11.5KEY STRATEGIES99
11.5.1PRODUCT LAUNCHES99
TABLE 80KEY PRODUCT LAUNCHES, JANUARY 2019–NOVEMBER 202299
11.5.2DEALS99
TABLE 81KEY DEALS, JANUARY 2019–AUGUST 202299
11.5.3OTHER DEVELOPMENTS100
TABLE 82OTHER KEY DEVELOPMENTS, JANUARY 2019–NOVEMBER 2022100
12COMPANY PROFILES101
12.1KEY PLAYERS101
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1ABBOTT LABORATORIES101
TABLE 83ABBOTT LABORATORIES: BUSINESS OVERVIEW101
FIGURE 25ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)102
12.1.2F. HOFFMANN-LA ROCHE AG104
TABLE 84F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW104
FIGURE 26F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021)104
12.1.3QIAGEN N.V.107
TABLE 85QIAGEN N.V.: BUSINESS OVERVIEW107
FIGURE 27QIAGEN N.V.: COMPANY SNAPSHOT (2021)108
12.1.4THERMO FISHER SCIENTIFIC, INC.111
TABLE 86THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW111
FIGURE 28THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)112
12.1.5ILLUMINA, INC.115
TABLE 87ILLUMINA, INC.: BUSINESS OVERVIEW115
FIGURE 29ILLUMINA, INC.: COMPANY SNAPSHOT (2021)116
12.1.6BIO-RAD LABORATORIES, INC.119
TABLE 88BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW119
FIGURE 30BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)120
12.1.7MOLECULARMD (A SUBSIDIARY OF ICON PLC)122
TABLE 89ICON PLC: BUSINESS OVERVIEW122
FIGURE 31ICON PLC: COMPANY SNAPSHOT (2021)122
12.1.8ADAPTIVE BIOTECHNOLOGIES124
TABLE 90ADAPTIVE BIOTECHNOLOGIES: BUSINESS OVERVIEW124
FIGURE 32ADAPTIVE BIOTECHNOLOGIES: COMPANY SNAPSHOT (2021)124
12.1.9ARCHERDX, INC. (A SUBSIDIARY OF INVITAE CORPORATION)126
TABLE 91ARCHERDX, INC.: BUSINESS OVERVIEW126
12.1.10ARUP LABORATORIES, INC.128
TABLE 92ARUP LABORATORIES, INC.: BUSINESS OVERVIEW128
12.1.11ASURAGEN, INC.130
TABLE 93ASURAGEN, INC.: BUSINESS OVERVIEW130
12.1.12INVIVOSCRIBE, INC.131
TABLE 94INVIVOSCRIBE, INC.: BUSINESS OVERVIEW131
12.1.13AMOY DIAGNOSTICS CO., LTD.133
TABLE 95AMOY DIAGNOSTICS CO., LTD.: BUSINESS OVERVIEW133
12.1.14ELITECHGROUP134
TABLE 96ELITECHGROUP: BUSINESS OVERVIEW134
12.1.15VELA DIAGNOSTICS135
TABLE 97VELA DIAGNOSTICS: BUSINESS OVERVIEW135
12.2OTHER PLAYERS136
12.2.1GENTRONIX LIMITED136
12.2.2BIOIVT136
12.2.3SAGA DIAGNOSTICS137
12.2.4OLINK137
12.2.5CANCER DIAGNOSTICS, INC.137
*Details on Business Overview, Products Offered, Recent Developments, and MnM View
(Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13APPENDIX138
13.1DISCUSSION GUIDE138
13.2KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL142
13.3CUSTOMIZATION OPTIONS144
13.4RELATED REPORTS144
13.5AUTHOR DETAILS145

Report Title: Hemato Oncology Testing Market by Product & Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid, Acute Lymphocytic), Lymphoma (Non-Hodgkin, Hodgkin), Technology (PCR, NGS), End User - Global Forecast to 2027


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW